Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications

Cancer Letters

Volumn 255, Issue 1, 2007, Pages 12-25

  Panani, Anna D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chromosomal abnormalities; Chronic myeloproliferative disorders; Clinical implications; Cytogenetics; JAK2 mutation; Molecular changes

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; HEMOGLOBIN; IMATINIB; JANUS KINASE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

CELL PROLIFERATION; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE CLASSIFICATION; EOSINOPHILIA; ERYTHROID CELL; GENE MUTATION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HYPEREOSINOPHILIA; MOLECULAR GENETICS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR GENE; SHORT SURVEY; SOMATIC MUTATION; THROMBOCYTHEMIA; THROMBOCYTOSIS; TRISOMY 8; VEIN THROMBOSIS;

EID: 34547771593     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.02.009     Document Type: Review

References (122)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6 (1951) 372-375
2. Pearson T.C. Diagnosis and classification of erythrocytosis and thrombocytosis. Baillieres Clin. Haematol. 11 (1998) 695-720
3. Bench A.J., Cross N.C.P., Huntly B.J.P., Nacheva E.P., and Green A.R. Myeloproliferative disorders. Best Pract. Res. Clin. Haematol. 14 (2001) 531-551
4. Bench A.J., Nacheva E.P., Champion K.M., and Green A.R. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Best Pract. Res. Clin. Haematol. 11 (1998) 819-848
5. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin. Proc. 78 (2003) 174-194
6. Thiele J., and Krasnicka H.M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann. Hematol. 82 (2003) 148-152
7. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin. Hematol. 36 (1999) 9-13
8. Murphy S., Peterson P., Iland H., and Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemia transition by treatment. Semin. Hematol. 34 (1997) 29-39
9. Blacklock H.A., and Royle G.A. Idiopathic erythocytosis: a declining entity. Br. J. Haematol. 115 (2001) 774-781
10. 32P between 1969 and 1981. Semin. Hematol. 34 (1997) 6-16
11. Spivak J.L. Polycythemia vera: myths, mechanisms and management. Blood 100 (2002) 4272-4290
12. Bench A.J., and Pahl H.L. Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin. Hematol. 42 (2005) 196-205
13. Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr. Opin. Hematol. 13 (2006) 87-92
14. Tefferi A., and Gilliland G. Classification of chronic myeloid disorders: from Dameshec towards a semi-molecular system. Best Pract. Res. Clin. Haematol. 19 (2006) 365-385
15. Tefferi A. Classic and atypical myeloproliferative disorders. Best Pract. Res. Clin. Haematol. 19 (2006) 361-364
16. Pardanani A., Ketterling R.P., Li C.-Y., Patnaik M.M., Wolanskyj A.P., Elliot M.A., Camoriano J.K., Butterfield J.H., Dewald G.W., and Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy and a critical review of the literature. Leuk. Res. 30 (2006) 965-970
17. Coutre S., and Gotlib J. Targeted treatment of hypereosinophilic syndrome and chronic eosinophilic leukemias with imatinib mesylate. Semin. Cancer Biol. 14 (2004) 23-31
18. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280 (2005) 22788-22792
19. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G., Bench A.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
20. Levine R.L., Wadleigh M., Cools J., Ebert B.J., Werning G., Huntly B.J.P., Boggon T.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
21. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Ugo V., Bennaceur-Griscelli A.., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (2005) 1144-1148
22. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain of function mutation in JAK2 is frequently found in patients with myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
23. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
24. Lennartsson J., Jelacic T., Linnekin D., and Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23 (2005) 16-43
25. Chen Z., and Sandberg A.A. Molecular cytogenetic aspects of hematological malignancies: clinical implications. Am. J. Med. Genet. (Semin. Med. Genet.) 115 (2002) 130-141
26. Diez Martin J.L., Graham D.L., Petitt R.M., and DeWald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin. Proc. 68 (1991) 287-299
27. Westwood N.B., Gruszka-Westwood A.M., Atkinson S., and Pearson T.C. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica 86 (2001) 464-469
28. Westwood N.B., Gruszka-Westwood A.M., Atkinson S., Pearson C.E., Delord C.F.M., Green A.R., Huntly B.J.P., Lakhani A., McMullin M.F., and Pearson T.C. The incidence of trisomy 8, trisomy 9 and D20S108 deletion in polycythemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br. J. Haematol. 110 (2000) 839-846
29. Najfeld V., Montella L., Scalise A., and Fruchtman S. Exploring polycythemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br. J. Haematol. 119 (2002) 558-566
30. Zamora L., Espinet B., Florensa L., Besses C., Woessner S., Serrano S., and Sole F. Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genet. Cytogenet. 151 (2004) 139-145
31. Gribble S.M., Reid A.G., Bench A.J., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Molecular cytogenetics of polycythemia vera: lack of occult rearrangements detectable by 20q LSP screening. CGH and M-FISH, Leuk. 17 (2003) 1419-1421
32. Chen Z., Notohamiprodjo M., Guan X.Y., Paietta E., Blackwell S., Stout K., Turner A., et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer 22 (1998) 321-324
33. Kralovics R., Buser A.S., Teo S.S., Coerts J., Tichelli A., Van Der Maas A.P., et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102 (2003) 1869-1871
34. Kralovics R., Guan Y.L., and Prchal J.T. Aquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30 (2002) 229-236
35. Montella L., Scalise A., Fruchtman S., and Najfeld V. Interphase FISH (I-FISH) in polycythemia vera (PV): a new tool for diagnosis and for providing insights into the biology of abnormal clones. Blood 94 Suppl. I (1999) 497
36. Tefferi A., Mesa R.A., Schroeder G., Hanson C.A., Li C.-Y., and Dewald G.W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 113 (2001) 763-771
37. Reilly J.T., Snowden J.A., Spearing R.L., Fitzgerald P.M., Jones N., Watmore A., and Potter A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br. J. Haematol. 98 (1997) 96-102
38. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., and Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
39. Tefferi A., Dingli D., Li C.-Y., and Dewald G.W. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 104 (2005) 1656-1660
40. Strasser-Weippl K., Steurer M., Kees M., Augustin F., Tzankov A., Dirnhofer S., Fiegl M., et al. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer 107 (2006) 2801-2806
41. Mesa R.A., Li C.-Y., Ketterling R.P., Schroeder G.S., Knudson R.A., and Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia:a single institution experience with 91 cases. Blood 105 (2005) 973-977
42. Strasser-Weippl K., Steurer M., Kees M., Augustin F., Tzankov A., Dirnhofer S., Fiegl M., et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4146
43. Dingli D., Schwager S.M., Mesa R.A., Li C.-Y., Dewald G.W., and Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 106 (2006) 1985-1989
44. Andrieux J., Demory J.L., Caulier M.T., Agape P., Watterwald M., Bauters F., and Lai J.L. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet. Cytogenet. 140 (2003) 118-123
45. Panani A.D. Cytogenetic findings in untreated patients with essential thrombocythemia. In Vivo 20 (2006) 381-384
46. Swolin B., Safai-Kutti S., Anghem E., and Kutti J. No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia. Cancer Genet. Cytogenet. 126 (2001) 56-59
47. Herishanu Y., Lishner M., Bomstein Y., Kitay-Cohen Y., Fejgin M.D., Gaber E., and Amiel A. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet. Cytogenet. 128 (2001) 154-157
48. Hirose Y., Masaki Y., and Sugai S. Leukemic transformation with trisomy 8 in essential thrombocythemia. Eur. J. Haematol. 68 (2002) 112-116
49. Lazarevic V.L., Tomin D., Jankovic G.M., Antic D., Dencic M., Gotic M., and Boskovic D. A novel t(2;17) in transformation of essential thrombocythemia to acute myeloid leukemia. Cancer Genet. Cytogenet. 148 (2004) 77-79
50. Bacher U., Haferlach T., Kern W., Hiddemann W., Schnittger S., and Schoch C. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann. Hematol. 84 (2005) 250-257
51. Kurtin P.J., Dewald G.W., Shields D.J., and Hanson C.A. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am. J. Clin. Pathol. 106 (1996) 680-688
52. Asimakopoulos F.A., White N.J., Nacheva E., and Green A.R. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84 (1994) 3086-3094
53. Nacheva E., Holloway T., Carter N., Grace C., White N., and Green A.R. Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes. Cancer Genet. Cytogenet. 80 (1995) 87-94
54. Bench A.J., Nacheva E., Hood T.L., Holden J.L., French L., Swanton S., et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. Oncogene 19 (2000) 3902-3913
55. Wang P.W., Iannantuoni K., Davis E.M., Espinosa III R., Stoffel M., and Beau M.M. Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 21 (1998) 75-81
56. Boccuni P., MacGrogan D., Scandura J.M., and Nimer S.D. The human L3MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL(ETV6). J. Biol. Chem. 278 (2003) 15412-15420
57. Bench A.J., Li J., Huntly B.J.P., Delabesse E., Fourouclas N., Hunt A.R., et al. Characterization of the imprinted polycomb gene L3MBTL a candidate 20q tumor suppressor gene, in patients with myeloid malignancies. Br. J. Haematol. 127 (2004) 509-518
58. MacGrogan D., Kalakonda N., Alvarez S., Scandura J.M., Boccuni P., Johansson B., et al. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes Cancer 41 (2004) 203-213
59. Panani A.D., and Roussos C. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. Cancer Lett. 235 (2006) 177-190
60. Aatola M., Armstrong E., Teerenhovi L., and Borgstrom G.H. Clinical significance of the del(20q) chromosome in hematologic disorders. Cancer Genet. Cytogenet. 62 (1992) 75-80
61. Campbell L.J., and Garson O.M. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8 (1994) 67-71
62. Brezinova J., Zemanova Z., Ransdorfova S., Sindelarova L., Siskova M., Neuwirtova R., et al. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet. Cytogenet. 160 (2005) 188-192
63. Chung C.Y., Kantarjian H., Haidar M., Starostic P., Manshouri T., Gidel C., et al. Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance. Cancer 88 (2000) 1359-1364
64. Gardiner A., Corcoran M., Ibbotson R., et al. An analysis of chromosome 13q14 deletions in myelofibrosis using FISH and Southern-based hybridization. Blood 90 Suppl. I (1997) 4062
65. Pastore C., Nomdedeu J., Volpe G., Guerrasio A., Cambrin G.R., Parvis G., Pautasso M., et al. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 14 (1995) 106-111
66. Al-Assar O., Ul-Hassan A., Brown R., Wilson G.A., Hammond D.W., and Reilly J.T. Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br. J. Haematol. 129 (2005) 66-71
67. Zojer N., Konigsberg R., Ackermann J., Fritz E., Dallinger S., Kromer E., Kaufmann H., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 (2000) 1925-1930
68. Rege Cambrin G., Speleman F., Kerin S., Scaravaglio P., Carozzi F., Dal Cin P., Michaux J.L., Offiner F., Saglio G., and Van Den Berghe H. Extra translocation +der(1q9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 5 (1991) 1059-1063
69. Andrieux J., Demory J.L., Dubriez B., Quief S., Plantier I., Roumier C., et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39 (2004) 82-87
70. Macdonald D., Reiter A., and Cross N.C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 107 (2002) 101-107
71. Chaffanet M., Popovici C., Leroux D., Jacrot M., Adelaide J., Dastugue N., et al. t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene 16 (1998) 945-949
72. Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Iqbal S., Parker S., et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 32 (2001) 155-163
73. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukemia/lymphoma syndrome. Nat. Genet. 18 (1998) 84-87
74. Popovici C., Zhang B., Gregoire M.J., Jonveaux P., Lafage-Pochitallof M., Bimbaum D., and Pebusque M.J. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93 (1999) 1381-1389
75. Xiao S., McCarthy J.G., Aster J.C., and Fletcher J.A. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. Blood 96 (2000) 699-704
76. Inhorn R.C., Aster J.C., Roach S.A., Slapak C.A., Soiffer R., Tantavahi R., and Stone R.M. A syndrome of lymphoblastic lymphoma, eosinophilia and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 85 (1995) 1881-1887
77. Steer E.J., and Cross N.C. Myeloproliferative disorders with translocations 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol. 107 (2002) 113-122
78. Baxter E.J., Kulkarni S., Vizmanos J.L., Jaju R., Martinelli G., Testoni N., Hughes G., et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRβ) gene in BCR/ABL negative chronic myeloproliferative disorders. Br. J. Haematol. 120 (2003) 251-256
79. Colub T.R., Barker G.G., Lovett M., and Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
80. Smith K.J., Jacobson E., Hamza S., and Shelton H.S. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetics analyses. Arch. Dermatol. 140 (2004) 584-588
81. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348 (2003) 1201-1214
82. Gotlib J., Cools J., Malone III J.M., Schrier S.L., Gilliland D.G., and Coutre S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management. Blood 103 (2004) 2879-2891
83. Gotlib J., Cross N.C.P., and Gilliland D.G. Eosinophilic disorders: molecular pathogenesis, new classification and modern therapy. Best Pract. Res. Clin. Haematol. 19 (2006) 535-569
84. Sambani C., La Starza R., Pierini V., Vandenberghe P., Gonzales-Aguilera J.J., Rigana H., Koumbi D., et al. Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genet. Cytogenet. 162 (2005) 45-49
85. Bacher U., Haferlach T., and Schoch C. Gain of 9p due to an unbalanced rearrangement der (9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genet. Cytogenet. 160 (2005) 179-183
86. Pahl H.L. Molecular markers in myeloproliferative disorders: from classification to prognosis?. Hematology 8 (2003) 199-209
87. Klippel S., and Pahl H.L. Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders. Pathol. Biol. 52 (2004) 267-274
88. Prchal J.T. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin. Hematol. 38 (2001) 10-20
89. Westwood N.B., and Pearson T.C. Diagnostic application of hemopoietic progenitor culture techniques in polycythemias and thrombocythemias. Leuk. Lymphoma 22 (1996) 95-103
90. Moliterno A.R., Hankins D., and Spivak J.L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. 338 (1998) 572-580
91. Klippel S., Strunck E., Temerinac S., Bench A.J., Meinhardt G., Mohr U., Leichtle R., Green A.R., Griesshammer M., Heimpel H., and Pahl H.L. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102 (2003) 3569-3574
92. Tefferi A., Lasho T.L., Wolanskyj A.P., and Mesa R.A. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 103 (2004) 3547-3548
93. Temerinac S., Klippel S., Strunck E., Roder S., Lubbert M., Lanqe W., Azemar M., et al. Cloning of PRV-1, a novel member of the Upar receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
94. Goerttler P.S., Kreutz C., Donauer J., Faller D., Maiwald T., Marz E., et al. Gene expression profiling in polycythemia vera: overexpression of transcription factor NF-E2. Br. J. Haematol. 129 (2005) 138-150
95. Chen G., and Prchal J.T. Polycythemia vera and molecular basis: an update. Best Pract. Res. Clin. Haematol. 19 (2006) 387-397
96. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br. J. Haematol. 134 (2006) 366-384
97. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
98. Bumm T.G.P., Elsea C., Corbin A.S., Loriaux M., Sherbenou D., Wood L., et al. Characterization of murine JAKV617F positive myeloproliferative disease. Cancer Res. 66 (2006) 11156-11165
99. Ganly P., Hanrahan V., Baker B., and Romeril K. Identification of JAK2 V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. Am. J. Hematol. 82 (2007) 80-82
100. Rossi D., Cortini F., Deambrogi C., Barbieri C., Cerri M., Franceschetti S., Conconi A., Capello D., and Gaidano G. Usefulness of JAK2 V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leuk. Res. 31 (2007) 97-101
101. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., White H., Zoi C., Loukopoulos D., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
102. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G., and Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
103. Levine R.L., Loriaux M., Huntly B.J.P., Loh M.L., Beran M., Stoffregen E., Barger R., Clark J.J., Willis S.G., Nguyen K.T., et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
104. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., Beran M., Estey E., Kantarjian H.M., and Issa J.-P.J. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
105. Tono C., Xu G., Toki T., Takahashi Y., Sasaki S., Terui K., et al. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia 19 (2005) 1843-1844
106. Scott L.M., Campbell P.J., Baxter E.J., Todd T., Stephens P., Edkins S., et al. The JAK2 V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106 (2005) 2920-2921
107. Sulong S., Case M., Minto L., Wilkins B., Hall A., and Irving J. The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukemia. Br. J. Haematol. 130 (2005) 964-972
108. Johan M.F., Goodeve A.C., Bowen D.T., Frew M.E., and Reitly J.T. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukemia. Br. J. Haematol. 130 (2005) 968
109. Nelson M.E., and Steensma D.P. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?. Leuk. Lymphoma 47 (2006) 177-194
110. Tefferi A., Sirhan S., Lasho T.L., Schwager S.M., Li C.-Y., Dingli D., Wolanskyj A., Steensma D.P., Mesa R.A., and Gilliland D.G. Concominant neutrophil JAK2 V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythemia. Br. J. Haematol. 131 (2005) 166-171
111. Kralovics R., Teo S.-S., Buser A.S., Brutsche M., Tiedt R., Tichelli A., Passamonti F., Pietra D., Cazzola M., and Skoda R.C. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2. Blood 106 (2005) 3374-3376
112. Tefferi A., Strand J.J., Lasho T.L., Elliot M., Li C.-Y., Mesa R., and Dewald G.W. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy. Cancer 106 (2006) 739-1743
113. Mesa R.A., Powell H., Lasho T.L., Dewald G.W., McClure R., and Tefferi A. JAK2 V617F and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk. Res. 30 (2006) 1457-1460
114. Rossi D., Deambrogi C., Capello D., Cerri M., Lunghi M., Parvis G., Saglio G., Gaidano G., and Cilloni D. JAK2 V617F mutation in leukemic transformation of Philadelphia negative chronic myeloproliferative disorders. Br. J. Haematol. 135 (2006) 267-268
115. Tefferi A., Lasho T.L., Schwager S.M., Strand J.S., Elliot M., Mesa R., Li C.-Y., et al. The clinical phenotype of wild-type, heterozygous and homozygous JAK2V617F in polycythemia vera. Cancer 106 (2006) 631-635
116. Ma W., Kantarjian H., Verstovsek S., Jilani I., Gorre M., Giles F., Cortes J., et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br. J. Haematol. 134 (2006) 341-342
117. M. Speletas, E. Katodritou, C. Daiou, E. Mandala, E. Papadakis, A. Kioumi, K. Ritis, I. Korantzis, Correlation of JAK2 V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders, Leuk. Res. available on line September 2006.
118. Tefferi A., Lasho T.L., Schwager S.M., Steensma D.P., Mesa R., Li C.-Y., et al. The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol. 131 (2005) 320-328
119. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.I., Marsden J.T., Duffy A., Boyd E.M., Bench A.J., et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
120. Heller P.G., Lev P.R., Salim J.P., Kornblihtt L.I., Goette N.P., Chazarreta C.D., Glembotsky A.C., S Vassallu P., Marta R.F., and Molimas F.C. JAK2 V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphprylation status. Eur. J. Haematol. 77 (2006) 210-216
121. Cheung B., Radia D., Pantelidis P., Yadegarfar G., and Harrison C. The presence of JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br. J. Haematol. 132 (2005) 244-250
122. Wolanskyj A., Lasho T.L., Schwager S.M., McClure R., Wadleigh M., Lee S.J., Gilliland D.G., and Tefferi A. JAK2 V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br. J. Haematol. 131 (2005) 208-213